Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
Open-label, no control groupHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 30 women with endometriosis enrolled. 28 completed.
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide twice a day for 10 days, then 400 mg of palmitoylethanolamide with 40 mg of polydatin twice a day for 80 days
- Duration
- 90 days, with a 30-day follow-up
- What was measured
- Pelvic pain and related symptoms on visual analogue scales, quality of life and psychological wellbeing questionnaires.
What the authors reported
Chronic pelvic pain scores fell from 7.2 to 2.6 (p < 0.0001), with smaller falls in period pain and other symptoms. Quality of life scores improved and use of pain medication fell. No adverse events were observed.
Limits of this study
A single-group study with no placebo and no blinding. The authors name the small sample, the open-label design and the short treatment period as limits. The funding statement was not visible on the page checked.
Source
Entry checked against the full text at the publisher (Dove Medical Press) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.